Effect of oral administration of microencapsulated lactic acid bacteria in a metabolic syndrome murine model

RUSSO, MATIAS; MÁRQUEZ, MARÍA ANTONELA; ABEIJÓN, MARÍA CLAUDIA; LÓPEZ MALO, AURELIO ; GAUFFIN CANO, PAOLA; MEDINA, ROXANA

San Miguel de Tucumán

Simposio; V International Symposium on Lactic Acid Bacteria; 2016

CERELA

EFFECT OF ORAL ADMINISTRATION OF MICROENCAPSULATED LACTIC ACID BACTERIA IN A METABOLIC SYNDROME MURINE MODELM. Russo1, A. Marquez1, M.C. Abeijón1,2, A. López-Malo3, P. Gauffin Cano1,2, R. Medina1,41CERELA-CONICET. Chacabuco 145. 4000. Tucumán, Argentina. 2UNSTA. 9 de Julio 165. 4000 Tucumán, Argentina. 3UDLAP. Hacienda Santa Catarina Mártir s/n. 72810. Cholula, Puebla, México. 4UNT. Ayacucho 491. 4000. Tucumán, Argentina. E-mail: mrusso@cerela.org.arMetabolic syndrome (MS) is a term used in recent years for a group of risk factors including visceral obesity, hypertension, hyperglycemia and atherogenic dyslipidemia, which predispose the individual to develop coronary artery disease and type 2 diabetes mellitus. Feruloyl esterases (FE) are enzymes that cause the hydrolytic release of ferulic acid (FA), present in plant foods. FA is a phenolic acid demonstrated antioxidant, hypoglycemic and lipid lowering activity. Lactobacillus fermentum CRL 1446 (L.f. CRL 1446) and Lactobacillus johnsonii CRL 1231 (L.j. CRL 1231) are potentially probiotic strains selected for their activity FE, capable of releasing FA in vitro. The administration of microencapsulated lactic acid bacteria (BAL) with FE activity could improve metabolic markers present in animal models of MS. The aim of the present work was to evaluate the effect of oral administration of L.f. CRL 1446 and L.j. CRL 1231 microcapsules on metabolic markers in a mice model of MS. Swiss male mice of 6 weeks old, were divided into six groups (n = 6) and fed daily for a period of 7 weeks with a standard diet (control group) and a hyperlipidemic diet (MS group). Mice received by gavage three types of microcapsules: empty (without treatment), with L.f. CRL 1446 (Lf group) or with L.j. CRL 1231 (Lj group). The administration dose was 107 CFU/day/mouse. Animals were sacrificed at week 7. Adiposity index was calculated. FE activity was determined in gut content using methylferulate as substrate. Released FA was detected by HPLC. Animal metabolic status was evaluated by determination of plasmatic glucose concentration and lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides). Results showed that body weight gain was higher after 7 weeks in mice MS group, which presented an index of adiposity significantly higher compared to controls, without differences between groups untreated, Lf and Lj. Total intestinal FE activity showed an increase of 1.16 fold in the case of mice Lf group and 1.12 fold for Lj mice compared to the untreated group. Plasma levels of fasting glucose were higher for the MS group compared to control group and a significant decrease in Lf group was observed compared to untreated mice. A significant reduction in the levels of total cholesterol, LDL-cholesterol and triglycerides in the Lf and Lj groups was also observed. According to the results, oral administration of L.f. CRL 1446 and L.j. CRL 1231 microcapsules increases intestinal FE activity and induce beneficial metabolic changes for the treatment of MS.